TGF-β suppresses type 2 immunity to cancer-Reference-Cited by-同舟云学术

TGF-β suppresses type 2 immunity to cancer

Published:2020-10-21 Issue:7832 Volume:587 Page:115-120
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Liu Ming^ORCID,Kuo Fengshen^ORCID,Capistrano Kristelle J.,Kang Davina,Nixon Briana G.,Shi Wei,Chou Chun,Do Mytrang H.,Stamatiades Efstathios G.,Gao Shengyu,Li Shun,Chen Yingbei^ORCID,Hsieh James J.^ORCID,Hakimi A. Ari^ORCID,Taniuchi Ichiro^ORCID,Chan Timothy A.^ORCID,Li Ming O.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-020-2836-1.pdf

Reference47 articles.

1. Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343–353 (2015).

2. Gause, W. C., Wynn, T. A. & Allen, J. E. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat. Rev. Immunol. 13, 607–614 (2013).

3. Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012).

4. DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405–409 (2012).

5. Dadi, S. et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365–377 (2016).

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs;International Immunopharmacology;2024-11

2. Secretory Nogo-B regulates Th2 differentiation in the lung cancer microenvironment;International Immunopharmacology;2024-10

3. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09

4. TGFβ in malignant canine mammary tumors: relation with angiogenesis, immunologic markers and prognostic role;Veterinary Quarterly;2024-08-20

5. High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy;Journal of Clinical Medicine;2024-08-13